A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy

An analysis of patients enrolled in GOG 172

Thomas C. Krivak, Chunqiao Tian, G. Scott Rose, Deborah Kay Armstrong, G. Larry Maxwell

Research output: Contribution to journalArticle

Abstract

Objective: Serum CA-125 values have been advocated in the monitoring of ovarian cancer patients receiving intravenous (IV) chemotherapy. This evaluation sought to determine if the CA-125 test can be used to monitor treatment effect among patients receiving intraperitoneal chemotherapy (IP). Methods: Patient charts from a phase III clinical trial (GOG 172) were retrospectively reviewed. Serum CA-125 levels prior to each cycle of therapy were collected and compared between the IV and IP chemotherapy delivery. The association between CA-125 and progression-free survival (PFS) or overall survival (OS) was estimated and the homogeneity of the results between IP and IV chemotherapy was assessed. Results: A total of 177 patients were treated with IV chemotherapy and 165 patients with IP chemotherapy with CA-125 data available were included in this analysis. The observed difference was not statistically significant in median CA-125 levels between the IV and IP arms at any time point (P > 0.05 for all). Following surgery and adjuvant chemotherapy, patients with an abnormal CA-125 > 35 U/ml were 2.45 times more likely to have disease progression (95% CI: 1.52-3.95, P <0.001) and 2.78 times more likely to die of disease (95% CI: 1.66-4.65, P <0.001), compared to those with a CA-125 <35 U/ml. These results were consistent with IP and IV chemotherapy. Conclusion: Serum CA-125 levels decrease in a similar manner during IP chemotherapy when compared to IV chemotherapy. Serum CA-125 algorithms for monitoring treatment effect that have been established for IV chemotherapy may also be applied for patients receiving IP chemotherapy.

Original languageEnglish (US)
Pages (from-to)81-85
Number of pages5
JournalGynecologic Oncology
Volume115
Issue number1
DOIs
StatePublished - Oct 2009

Fingerprint

Ovarian Neoplasms
Drug Therapy
Serum
Phase III Clinical Trials
Adjuvant Chemotherapy
Disease-Free Survival
Disease Progression

Keywords

  • CA-125
  • Intraperitoneal chemotherapy
  • Ovarian cancer

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

@article{6a88de635eed4919b27eec915bd09ecf,
title = "A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: An analysis of patients enrolled in GOG 172",
abstract = "Objective: Serum CA-125 values have been advocated in the monitoring of ovarian cancer patients receiving intravenous (IV) chemotherapy. This evaluation sought to determine if the CA-125 test can be used to monitor treatment effect among patients receiving intraperitoneal chemotherapy (IP). Methods: Patient charts from a phase III clinical trial (GOG 172) were retrospectively reviewed. Serum CA-125 levels prior to each cycle of therapy were collected and compared between the IV and IP chemotherapy delivery. The association between CA-125 and progression-free survival (PFS) or overall survival (OS) was estimated and the homogeneity of the results between IP and IV chemotherapy was assessed. Results: A total of 177 patients were treated with IV chemotherapy and 165 patients with IP chemotherapy with CA-125 data available were included in this analysis. The observed difference was not statistically significant in median CA-125 levels between the IV and IP arms at any time point (P > 0.05 for all). Following surgery and adjuvant chemotherapy, patients with an abnormal CA-125 > 35 U/ml were 2.45 times more likely to have disease progression (95{\%} CI: 1.52-3.95, P <0.001) and 2.78 times more likely to die of disease (95{\%} CI: 1.66-4.65, P <0.001), compared to those with a CA-125 <35 U/ml. These results were consistent with IP and IV chemotherapy. Conclusion: Serum CA-125 levels decrease in a similar manner during IP chemotherapy when compared to IV chemotherapy. Serum CA-125 algorithms for monitoring treatment effect that have been established for IV chemotherapy may also be applied for patients receiving IP chemotherapy.",
keywords = "CA-125, Intraperitoneal chemotherapy, Ovarian cancer",
author = "Krivak, {Thomas C.} and Chunqiao Tian and Rose, {G. Scott} and Armstrong, {Deborah Kay} and Maxwell, {G. Larry}",
year = "2009",
month = "10",
doi = "10.1016/j.ygyno.2009.06.021",
language = "English (US)",
volume = "115",
pages = "81--85",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy

T2 - An analysis of patients enrolled in GOG 172

AU - Krivak, Thomas C.

AU - Tian, Chunqiao

AU - Rose, G. Scott

AU - Armstrong, Deborah Kay

AU - Maxwell, G. Larry

PY - 2009/10

Y1 - 2009/10

N2 - Objective: Serum CA-125 values have been advocated in the monitoring of ovarian cancer patients receiving intravenous (IV) chemotherapy. This evaluation sought to determine if the CA-125 test can be used to monitor treatment effect among patients receiving intraperitoneal chemotherapy (IP). Methods: Patient charts from a phase III clinical trial (GOG 172) were retrospectively reviewed. Serum CA-125 levels prior to each cycle of therapy were collected and compared between the IV and IP chemotherapy delivery. The association between CA-125 and progression-free survival (PFS) or overall survival (OS) was estimated and the homogeneity of the results between IP and IV chemotherapy was assessed. Results: A total of 177 patients were treated with IV chemotherapy and 165 patients with IP chemotherapy with CA-125 data available were included in this analysis. The observed difference was not statistically significant in median CA-125 levels between the IV and IP arms at any time point (P > 0.05 for all). Following surgery and adjuvant chemotherapy, patients with an abnormal CA-125 > 35 U/ml were 2.45 times more likely to have disease progression (95% CI: 1.52-3.95, P <0.001) and 2.78 times more likely to die of disease (95% CI: 1.66-4.65, P <0.001), compared to those with a CA-125 <35 U/ml. These results were consistent with IP and IV chemotherapy. Conclusion: Serum CA-125 levels decrease in a similar manner during IP chemotherapy when compared to IV chemotherapy. Serum CA-125 algorithms for monitoring treatment effect that have been established for IV chemotherapy may also be applied for patients receiving IP chemotherapy.

AB - Objective: Serum CA-125 values have been advocated in the monitoring of ovarian cancer patients receiving intravenous (IV) chemotherapy. This evaluation sought to determine if the CA-125 test can be used to monitor treatment effect among patients receiving intraperitoneal chemotherapy (IP). Methods: Patient charts from a phase III clinical trial (GOG 172) were retrospectively reviewed. Serum CA-125 levels prior to each cycle of therapy were collected and compared between the IV and IP chemotherapy delivery. The association between CA-125 and progression-free survival (PFS) or overall survival (OS) was estimated and the homogeneity of the results between IP and IV chemotherapy was assessed. Results: A total of 177 patients were treated with IV chemotherapy and 165 patients with IP chemotherapy with CA-125 data available were included in this analysis. The observed difference was not statistically significant in median CA-125 levels between the IV and IP arms at any time point (P > 0.05 for all). Following surgery and adjuvant chemotherapy, patients with an abnormal CA-125 > 35 U/ml were 2.45 times more likely to have disease progression (95% CI: 1.52-3.95, P <0.001) and 2.78 times more likely to die of disease (95% CI: 1.66-4.65, P <0.001), compared to those with a CA-125 <35 U/ml. These results were consistent with IP and IV chemotherapy. Conclusion: Serum CA-125 levels decrease in a similar manner during IP chemotherapy when compared to IV chemotherapy. Serum CA-125 algorithms for monitoring treatment effect that have been established for IV chemotherapy may also be applied for patients receiving IP chemotherapy.

KW - CA-125

KW - Intraperitoneal chemotherapy

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=69249217753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69249217753&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2009.06.021

DO - 10.1016/j.ygyno.2009.06.021

M3 - Article

VL - 115

SP - 81

EP - 85

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -